Moderna Pursues mRNA Flu/COVID Combo Vaccine Despite Financial Struggles
-
Moderna's mRNA-1083 vaccine targets both COVID-19 and influenza, with Phase 3 trials underway and potential approval in 2025. This could be a lucrative product given the large market.
-
Moderna's Q3 2023 financial results showed decreased revenue and increased costs, resulting in a net loss versus a profit last year. Cash reserves remain strong.
-
Moderna expects its respiratory products, including mRNA-1083, to generate $8-15 billion in sales by 2027, capturing significant market share.
-
Competition from Pfizer's rival vaccine could limit Moderna's market penetration and revenue growth from mRNA-1083.
-
Beyond COVID-19 vaccines, Moderna's mRNA pipeline includes cancer and infectious disease treatments, providing future diversified revenue streams.